Nebulized Furosemide for Pulmonary Inflammation in Intubated Patients With COVID-19: A Phase 2 Randomized Controlled Double-Blind Study.

ABSTRACT:

Objectives

Respiratory failure secondary to COVID-19 is associated with morbidity and mortality. Current anti-inflammatory therapies are effective but are given systemically and have significant side effects. Furosemide has anti-inflammatory properties, can be administered by inhalation, and is inexpensive. We investigated the efficacy of nebulized furosemide as an adjunctive therapy for COVID-19 respiratory failure.

Design

A double-blind, randomized, placebo-controlled trial.

Setting

Multicenter ICU study.

Patients

Adults requiring invasive mechanical ventilation secondary to COVID-19.

Intervention

Patients were randomized within 48 hours of intubation to receive inhaled furosemide or placebo until day 28, death, or liberation from mechanical ventilatio

SUBMITTER: Muscedere J 

PROVIDER: S-EPMC10954058 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature